Clinical Evaluation of Trimethoprim-Containing Ophthalmic Solutions in Humans

https://doi.org/10.1016/0002-9394(84)90181-8Get rights and content

We studied trimethoprim in combination with sulfacetamide and polymyxin B and also in combination with polymyxin B alone (without the sulfacetamide) to determine the efficacy and safety of these new antibiotic combinations in the eyes of patients with bacterial conjunctivitis or blepharitis. Patients were selected for the study if they showed at least three of the following criteria: (1) symptoms of a surface ocular infection; (2) a purulent discharge; (3) a polymorphonuclear neutrophilic response on Giemsa stain; (4) a history of recent exposure to an infected individual; (5) a history of an inadequately treated surface bacterial infection. Trimethoprim-sulfacetamide-polymyxin B and polymyxin B-neomycin-gramicidin (Neosporin, the control) eliminated bacteria from the eyes of patients with conjunctivitis or blepharitis with equal effectiveness. There was no loss of effectiveness when trimethoprim-polymyxin B was compared with trimethoprim-sulfacetamide-polymyxin B, suggesting that the sulfacetamide was not a necessary component. The combination antibiotic containing trimethoprim and polymyxin B appears to be an effective topical antibiotic solution for the treatment of ocular surface infections.

References (6)

  • E. Genáe et al.

    Trimethoprim-polymyxin B eye drops versus neomycin-polymyxin-gramicidin eye drops in the treatment of presumptive bacterial conjunctivitis. A double blind study

    Ophthalmologica

    (1982)
  • S.F. van Rensburg et al.

    Trimethoprim-polymyxin ophthalmic solution versus chloramphenicol ophthalmic solution in the treatment of bacterial conjunctivitis

    Pharmatherapeutica

    (1982)
  • L. Cason et al.

    Bacteriology of the eye. Normal flora

    Arch. Ophthalmol.

    (1954)
There are more references available in the full text version of this article.

Cited by (11)

  • Update on emerging infections: News from the Centers for Disease Control and Prevention

    2002, Annals of Emergency Medicine
    Citation Excerpt :

    Topical therapy with sodium sulfacetamide (eg, Bleph 10) has also been commonly used; however, resistance exists among a significant percentage of staphylococcal isolates, and it does not provide adequate coverage against Neisseria species, Serratia marcescens , and Pseudomonas aeruginosa.10 Also, the addition of sulfacetamide to trimethoprim-containing topical ophthalmic solutions (eg, trimethoprim-polymyxin B) has not been shown to produce improved clinical and microbiologic efficacy.11,12 Antibiotic coverage should be extended to cover for Pseudomonas if the patient wears contact lenses (eg, fluoroquinolone or an aminoglycoside).

View all citing articles on Scopus

This study was supported in part by a grant from Research to Prevent Blindness, Inc., New York, New York, and by Burroughs Wellcome Co., Research Triangle Park, North Carolina.

Reprint requests to David W. Lamberts, M.D., Cornea Service, Department of Ophthalmology, Texas Tech University School of Medicine, Lubbock, TX 79430.

1

Dr. Buka is in private practice in Cincinnati, Ohio.

View full text